Aditxt, Inc. (NASDAQ

ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023

Aditxt, Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will participate in the H.C. Wainwright 25^th Annual Global Investment Conference being held September 11^th -13^th, 2023, in New York City. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feeds or available on-demand.

Aditxt Chairman, Co-Founder, and Chief Executive Officer Amro Albanna will deliver the company presentation September 13^th, from 4:30 p.m. to 5:00 p.m. EDT. If you are an institutional investor, and would like to listen to the Company’s presentation, please register here. Over 550 corporate presentations and panels are available during September 11^th -13^th, 2023.

To schedule a one-on-one meeting with the Aditxt management team, please contact your conference representative.

H.C. Wainwright 25^th Annual Global Investment Conference
Date: September 11^th to 13^th, 2023
Aditxt Presentation time and date: September 13, 2023, from 4:30 p.m. to 5:00 p.m.
Speaker: Amro Albanna, Chairman, Co-Founder, and Chief Executive Officer, Aditxt, Inc.
Location: Virtual attendees link here. In-person: Lotte New York Palace Hotel, 455 Madison Ave, New York City.

About Aditxt, Inc.

Aditxt, Inc. (NASDAQ: ADTX) a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Headquartered in Richmond, Virginia, with operations in Mountain View, California, and Melville, New York. Aditxt’s mission of “Making Promising Innovations Possible, Together” is defined by our growing ecosystem of research institutions, global industry partners, and shareholders who inform and inspire our mission. Aditxt’s diverse innovation portfolio includes: Adimune, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at their CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.